Cargando…
Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
The overall survival rate of patients with osteosarcoma has remained stagnant at 15–30% for several decades. Although immunotherapy has revolutionized the oncology field, largely attributed to the success of immune-checkpoint blockade, the durability and efficacy of anti-PD1 (programmed cell death p...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593232/ https://www.ncbi.nlm.nih.gov/pubmed/31293882 http://dx.doi.org/10.1016/j.jbo.2019.100245 |